Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-Linolenic Acid (ALA) is an omega-3 fatty acid found in plant sources such as flaxseed, chia seeds, and walnuts. Its use in Inflammatory Bowel Disorders (IBD)—including Crohn’s disease and ulcerative colitis—is primarily based on the anti-inflammatory properties of omega-3 fatty acids. Scientific interest stems from the role of pro-inflammatory eicosanoids in IBD pathogenesis and the observation that omega-3 fatty acids may modulate inflammatory responses.

Several clinical studies and animal models suggest that omega-3 fatty acids can reduce inflammation in IBD; however, most of this research focuses on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from fish oil, rather than ALA. ALA itself must be converted in the body to EPA and DHA, a process that is inefficient in humans. Some studies indicate that ALA-rich diets may modestly reduce inflammatory markers, but direct evidence for ALA supplementation improving IBD outcomes is limited and inconsistent.

Systematic reviews and meta-analyses (e.g., Cochrane reviews) generally conclude that omega-3 fatty acid supplementation may have a slight anti-inflammatory effect but does not provide strong or consistent clinical benefit in maintaining remission or reducing relapse rates in IBD. Therefore, while there is some biological plausibility and limited scientific evidence supporting ALA’s use in IBD, the overall quality and consistency of evidence are low.

Summary: The use of ALA for IBD is supported by modest scientific evidence, primarily extrapolated from research on other omega-3 fatty acids. Its clinical benefit remains unproven, and guidelines do not strongly recommend ALA supplementation for IBD management.

More about Alpha-Linolenic Acid
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Alpha-Linolenic Acid

Products containing Alpha-Linolenic Acid